MA33332B1 - Dérivés de la 1h-imidazo[4,5-c]quinolinone - Google Patents
Dérivés de la 1h-imidazo[4,5-c]quinolinoneInfo
- Publication number
- MA33332B1 MA33332B1 MA34404A MA34404A MA33332B1 MA 33332 B1 MA33332 B1 MA 33332B1 MA 34404 A MA34404 A MA 34404A MA 34404 A MA34404 A MA 34404A MA 33332 B1 MA33332 B1 MA 33332B1
- Authority
- MA
- Morocco
- Prior art keywords
- imidazo
- quinolinone
- kinase
- derivatives
- treatment
- Prior art date
Links
- IQYPSFAWXDKDBA-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-c]quinolin-2-one Chemical compound C1=CC=CC2=C(NC(=O)N3)C3=CN=C21 IQYPSFAWXDKDBA-UHFFFAOYSA-N 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 102000001253 Protein Kinase Human genes 0.000 abstract 3
- 108060006633 protein kinase Proteins 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229930185107 quinolinone Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE L'UTILISATION DE DÉRIVÉS DE LA 1H-IMIDAZO[4,5-C]QUINOLINONE ET DE LEURS SELS DANS LE TRAITEMENT DE MALADIES DÉPENDANTES D'UNE PROTÉINE-KINASE ET/OU D'UNE LIPIDE-KINASE ET DANS LA FABRICATION DE PRÉPARATIONS PHARMACEUTIQUES POUR LE TRAITEMENT DESDITES MALADIES. L'INVENTION CONCERNE DES DÉRIVÉS DE LA 1H-IMIDAZO[4,5-C] QUINOLINONE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES DÉPENDANTES D'UNE PROTÉINE-KINASE ET/OU D'UNE LIPIDE-KINASE, UN PROCÉDÉ DE TRAITEMENT CONTRE LESDITES MALADIES, CONSISTANT À ADMINISTRER LES DÉRIVÉS DE LA 1H- IMIDAZO[4,5-C] QUINOLINONE À UN ANIMAL À SANG CHAUD, PARTICULIÈREMENT UN HUMAIN, DES PRÉPARATIONS PHARMACEUTIQUES COMPRENANT UN DÉRIVÉ DE LA 1H-IMIDAZO[4,5-C] QUINOLINONE, PARTICULIÈREMENT POUR LE TRAITEMENT D'UNE MALADIE DÉPENDANTE D'UNE PROTÉINE-KINASE ET/OU D'UNE LIPIDE-KINASE, DE NOUVEAUX DÉRIVÉS DE LA H- IMIDAZO[4,5-C] QUINOLINONE, ET UN PROCÉDÉ DE PRÉPARATION DES NOUVEAUX DÉRIVÉS DE LA 1H- IMIDAZO[4,5-C] QUINOLINONE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18414109P | 2009-06-04 | 2009-06-04 | |
| PCT/EP2010/057719 WO2010139731A1 (fr) | 2009-06-04 | 2010-06-02 | Dérivés de la 1h-imidazo[4,5-c]quinolinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33332B1 true MA33332B1 (fr) | 2012-06-01 |
Family
ID=42697442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34404A MA33332B1 (fr) | 2009-06-04 | 2010-06-02 | Dérivés de la 1h-imidazo[4,5-c]quinolinone |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8476294B2 (fr) |
| EP (1) | EP2438064A1 (fr) |
| JP (1) | JP5596137B2 (fr) |
| KR (1) | KR101445458B1 (fr) |
| CN (1) | CN102574845B (fr) |
| AR (1) | AR076949A1 (fr) |
| AU (1) | AU2010255727B2 (fr) |
| BR (1) | BRPI1010621A2 (fr) |
| CA (1) | CA2763821A1 (fr) |
| CL (1) | CL2011003052A1 (fr) |
| CO (1) | CO6470887A2 (fr) |
| CR (1) | CR20110608A (fr) |
| CU (1) | CU24064B1 (fr) |
| DO (1) | DOP2011000373A (fr) |
| EA (1) | EA020715B1 (fr) |
| EC (1) | ECSP11011500A (fr) |
| GE (1) | GEP20156267B (fr) |
| IL (1) | IL216452A0 (fr) |
| MA (1) | MA33332B1 (fr) |
| MX (1) | MX2011012943A (fr) |
| NI (1) | NI201100209A (fr) |
| NZ (1) | NZ596487A (fr) |
| PE (1) | PE20120224A1 (fr) |
| SG (1) | SG176572A1 (fr) |
| TN (1) | TN2011000626A1 (fr) |
| TW (1) | TWI464168B (fr) |
| UA (1) | UA106074C2 (fr) |
| UY (1) | UY32682A (fr) |
| WO (1) | WO2010139731A1 (fr) |
| ZA (1) | ZA201108439B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| AR084731A1 (es) * | 2010-12-06 | 2013-06-05 | Piramal Life Sciences Ltd | Derivados de imidazoquinolina sustituidos |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| EP2781520B1 (fr) * | 2011-11-17 | 2016-05-04 | Xuanzhu Pharma Co., Ltd. | Inhibiteur tricyclique de pi3k et/ou mtor |
| WO2014141118A1 (fr) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Dérivés d'imidazo[4,5-c]quinoléine et leurs utilisations |
| KR102227271B1 (ko) | 2013-04-15 | 2021-03-12 | 에프엠씨 코포레이션 | 살진균성 아미드 |
| JP6576929B2 (ja) * | 2013-09-11 | 2019-09-18 | メルク パテント ゲーエムベーハー | ヘテロ環化合物 |
| JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
| WO2015053402A1 (fr) * | 2013-10-11 | 2015-04-16 | 国立大学法人東京医科歯科大学 | Médicament pour la prévention ou le traitement de la dégénérescence spinocérébelleuse |
| US10047084B2 (en) | 2013-11-20 | 2018-08-14 | Beijing Forelandpharma Co. Ltd. | Imidazolone derivatives, pharmaceutical compositions and uses thereof |
| NO2714752T3 (fr) | 2014-05-08 | 2018-04-21 | ||
| TN2016000542A1 (en) | 2014-06-03 | 2018-04-04 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as t-type calcium channel blockers |
| PL3277681T3 (pl) | 2015-04-02 | 2019-10-31 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| CN110023312A (zh) | 2016-10-13 | 2019-07-16 | 由卫生与公众服务部部长代表的美利坚合众国 | 阻止疟疾寄生虫传播的化合物和方法 |
| HRP20220463T1 (hr) | 2016-12-16 | 2022-05-27 | Idorsia Pharmaceuticals Ltd | Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa |
| WO2018141961A1 (fr) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| WO2019126731A1 (fr) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| WO2021061803A1 (fr) * | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Inhibiteurs de phosphodiestérase et leur utilisation |
| BR112022023559A2 (pt) * | 2020-05-21 | 2023-01-24 | Stemsynergy Therapeutics Inc | Inibidores de notch e seus usos |
| CN116056698B (zh) | 2020-09-21 | 2024-11-19 | 威尚（上海）生物医药有限公司 | 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物 |
| US20230380203A1 (en) * | 2021-01-26 | 2023-11-23 | Boe Technology Group Co., Ltd. | Quantum dot light-emitting device, display apparatus and manufacturing method |
| CA3229855A1 (fr) * | 2021-08-31 | 2023-03-09 | Incyte Corporation | Composes de naphtyridine en tant qu'inhibiteurs de kras |
| CN116768928B (zh) * | 2023-06-15 | 2026-07-17 | 上海毕臣生化科技有限公司 | 一种3-叔丁基-5-硼酸酯基吡啶的合成方法 |
| CN117384154A (zh) * | 2023-09-04 | 2024-01-12 | 广州医科大学 | 一种吡咯并喹啉酮化合物、合成方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| RU2006121646A (ru) | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ES2429170T3 (es) | 2005-11-04 | 2013-11-13 | 3M Innovative Properties Company | 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos |
| CA2669199C (fr) | 2006-11-20 | 2015-12-29 | Novartis Ag | Sels et formes cristallines de 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| RU2478387C2 (ru) * | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
| WO2009013305A1 (fr) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Utilisation d'imidazoquinolines pour le traitement de maladies dépendant de egfr ou de maladies qui ont acquis une résistance à des agents qui ciblent des membres de la famille egfr |
| US20090082387A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| EP2474323A3 (fr) | 2008-03-26 | 2012-10-10 | Novartis AG | Dérivés d'imidazoquinoline et de pyrimidine en tant que modulateurs puissants de processus angiogènes à commande VEGF |
| EP2303890A4 (fr) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | Inhibiteurs de phosphatidylinositol 3 kinase |
| US8791131B2 (en) | 2008-09-30 | 2014-07-29 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 CA CA2763821A patent/CA2763821A1/fr not_active Abandoned
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active Expired - Fee Related
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/fr not_active Ceased
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 EP EP10721029A patent/EP2438064A1/fr not_active Withdrawn
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
-
2011
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000626A1 (en) | 1h-imidazo[4,5-c]quinolinone derivatives | |
| MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
| BR0311221A (pt) | Derivados de 1h-imidazo[4,5-c]quinolina no tratamento de doenças dependentes de proteìna cinase | |
| MA30967B1 (fr) | Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile. | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA32230B1 (fr) | Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one | |
| MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| TN2012000074A1 (fr) | Derives de thieno [2, 3-b] pyridine servant d'inhibiteurs de replication virale | |
| DE602007004093D1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| KR20090087009A (ko) | 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법 | |
| JP2017514914A (ja) | ブルートンチロシンキナーゼ阻害剤 | |
| JP2016538254A (ja) | 腸透過性亢進を治療するための組成物及び方法 | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| BRPI0509468A (pt) | 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas | |
| MX393035B (es) | Inhibidor de aldosterona sintasa | |
| TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
| KR20180099910A (ko) | 치료 방법 | |
| EA201291114A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА | |
| JP5446271B2 (ja) | アデニン由来化合物のループス治療への使用 | |
| Senturk et al. | In Vitro and In Silico Calculation of Melatonin and Dopamine on Acetylcholinesterase and Butyrylcholinesterase |